Peptides Similar to HGH Fragment 176-191

Peptides Related to HGH Fragment 176-191#

Several peptides share functional overlap with HGH Fragment 176-191 in tissue repair and healing research. Below is a detailed comparison of their mechanisms, efficacy, and potential for combination use.

Thymosin Beta-4 (TB-500)#

We compared HGH Fragment 176–191 (AOD9604), Thymosin beta‑4/TB‑500, and GHK‑Cu across metabolic and tissue‑repair domains and assessed evidence strength, outcomes, and safety. No head‑to‑head studies among these peptides were identified in retrieved evidence.

Metabolic/fat loss

• AOD9604: Six randomized, double‑blind, placebo‑controlled trials (Phase I–IIb; ~900 adults) establish placebo‑like safety, no IGF‑1 elevation, and no adverse effects on glucose tolerance; efficacy trials targeted weight/fat reduction, but the retrieved summaries do not report quantitative weight‑loss effects, leaving the magnitude of clinical benefit unclear (human RCTs; strong safety, uncertain efficacy signal). Preclinical models in obese mice and β3‑adrenergic receptor knockout mice show increased fat oxidation and reduced adiposity, supporting a direct adipose metabolic mechanism (animal).
• Thymosin beta‑4/TB‑500 and GHK‑Cu: No metabolic/weight‑loss RCTs found in retrieved records; these agents are primarily studied for tissue repair rather than fat loss (evidence gap).

Wound and tissue repair

• Thymosin beta‑4/TB‑500: The most advanced human data in tissue repair. Ophthalmic RGN‑259 (Tβ4 eye drops) completed ARISE‑1/2/3 multicenter randomized trials in dry eye with prespecified symptom and corneal staining endpoints (human Phase 2/3); clinicaltrials.gov records confirm designs and completion, though numerical outcomes are not in the retrieved excerpts (human) (NCT02597803, NCT02974907). Phase 2 randomized, placebo‑controlled trials in pressure ulcers and venous stasis ulcers were completed with wound closure endpoints at Day 84 (human) (NCT00382174, NCT00832091). Mechanistic and animal studies indicate enhanced corneal and dermal healing, angiogenesis, and inflammation resolution, including activation of specialized pro‑resolving mediator pathways in corneal infection models (animal/mechanistic) (NCT00382174, NCT00832091).
• GHK‑Cu: Broad preclinical support for accelerated wound healing, angiogenesis, and anti‑inflammatory/antioxidant effects, with reports of cosmetic/clinical improvements in skin parameters; animal models show faster wound closure and benefits in fibrotic lung injury (animal; small clinical/cosmetic signals) (workUnknownyearwhatisghkcu? pages 1-2, workUnknownyearwhatisghkcu? pages 2-3). Specific animal studies using GHK‑Cu formulations demonstrate enhanced scald wound healing (animal) (workUnknownyearwhatisghkcu? pages 2-3).
• AOD9604: Evidence base is focused on metabolism; no human tissue‑repair trials were identified in retrieved records.

Ocular surface disease

• Thymosin beta‑4/TB‑500: RGN‑259 completed ARISE‑1/2/3 randomized trials with primary endpoints including corneal fluorescein staining and ocular discomfort; records confirm completion and outcome domains (human) (NCT02597803, NCT02974907). Preclinical work supports pro‑healing and anti‑inflammatory mechanisms on the ocular surface (animal/mechanistic) (NCT00382174).
• GHK‑Cu and AOD9604: No ocular RCTs retrieved.

Musculoskeletal/tendon/ligament repair

• GHK‑Cu: Animal evidence includes improved healing kinetics and matrix remodeling in wound models; broader connective tissue benefits are supported preclinically (animal) (workUnknownyearwhatisghkcu? pages 1-2, workUnknownyearwhatisghkcu? pages 2-3).
• Thymosin beta‑4/TB‑500: Animal/mechanistic data support enhanced cell migration, angiogenesis, and repair; clinical trials have focused on ocular and chronic skin ulcers rather than tendon/ligament (animal; human in other tissues) (NCT00382174, NCT00832091).
• AOD9604: No musculoskeletal repair studies retrieved.

Organ repair (heart, kidney, lung)

• Thymosin beta‑4/TB‑500: Clinical programs include completed Phase 2 studies in acute myocardial infarction (AMI) and early‑phase healthy volunteer studies (human feasibility/safety) (NCT02974907). Mechanistic and animal data indicate tissue‑protective and pro‑resolving effects (animal/mechanistic) (NCT00382174).
• GHK‑Cu: Animal studies show protection in lung injury and fibrosis models, with reductions in inflammatory cytokines and oxidative stress (animal) (workUnknownyearwhatisghkcu? pages 2-3, workUnknownyearwhatisghkcu? pages 1-2).
• AOD9604: No organ‑repair studies retrieved.

Safety

• AOD9604: Across six RCTs, safety indistinguishable from placebo, no IGF‑1 increase, and no adverse effects on carbohydrate metabolism; most adverse events were mild (e.g., headache, GI) (human RCTs).
• Thymosin beta‑4/TB‑500: Ophthalmic and topical formulations in completed trials were well‑tolerated per registry summaries; detailed AE rates not present in retrieved excerpts (human) (NCT00382174, NCT02974907, NCT02597803).
• GHK‑Cu: Favorable safety record in cosmetic use; formal trial‑grade AE reporting is limited in retrieved summaries (human experience; preclinical safety supportive) (workUnknownyearwhatisghkcu? pages 1-2).

Head‑to‑head or combination studies

• No head‑to‑head randomized comparisons among AOD9604, Thymosin beta‑4/TB‑500, and GHK‑Cu were identified; studies occur in largely non‑overlapping indications (no direct comparative efficacy available).

Overall comparative efficacy assessment

• For obesity/fat loss, AOD9604 has the strongest human randomized exposure but an uncertain efficacy signal in accessible summaries; neither Thymosin beta‑4 nor GHK‑Cu have comparable weight‑loss trials.
• For wound/tissue repair, Thymosin beta‑4 has the most advanced human data (ophthalmic dry eye and chronic ulcers) supported by robust preclinical mechanisms; GHK‑Cu shows consistent preclinical pro‑healing activity with smaller human cosmetic/wound signals; AOD9604 lacks tissue‑repair trials (NCT02597803, NCT02974907, NCT00382174, NCT00832091, workUnknownyearwhatisghkcu? pages 1-2, workUnknownyearwhatisghkcu? pages 2-3).

Bottom-line comparative assessment:

1. AOD9604 (HGH 176–191) — largest human RCT exposure for obesity (Phase I–IIb, ~900 subjects); efficacy signal unclear in retrieved summaries.
2. Thymosin β4 / TB‑500 — most advanced human data for tissue repair (ophthalmic RGN‑259 ARISE-1/2/3; pressure/venous stasis ulcer Phase 2 trials) with consistent mechanistic and animal support for wound healing and inflammation resolution. (NCT02974907, NCT02597803, NCT00382174, NCT00832091)
3. GHK‑Cu — strong preclinical evidence for pro‑healing, angiogenesis and anti‑inflammatory effects and small clinical/cosmetic wound/skin reports; limited rigorous RCT data. (workUnknownyearwhatisghkcu? pages 1-2, workUnknownyearwhatisghkcu? pages 2-3)
4. No head‑to‑head RCTs or direct comparative trials among these peptides were identified in retrieved evidence.
5. Safety: AOD9604 showed placebo‑like safety and no IGF‑1 elevation in trials; TB‑4 ophthalmic/topical formulations were well‑tolerated in completed trials; GHK‑Cu has a favorable cosmetic safety record but formal trial safety data are limited.

Blockquote: A concise, cited summary comparing the evidence strength, main outcomes, gaps (no head-to-head trials), and safety signals for AOD9604, Thymosin β4/TB‑500, and GHK‑Cu; useful as a quick reference to where human RCTs exist and where evidence remains preclinical.

Mechanism Comparison#

Which peptides share overlapping mechanisms? • Overlap in net effect but not receptor/signaling: AOD9604 and full‑length GH both increase lipolysis/fat oxidation and reduce lipogenesis; however, GH does so via GHR→JAK2/STAT5, PI3K, and MAPK, while AOD9604 appears GHR‑independent with unresolved signaling. • Indirect overlap via GH axis: GHRH analogs (tesamorelin/CJC‑1295) reduce visceral fat by elevating endogenous GH, engaging GHR signaling and thereby recapitulating GH‑like adipose lipolysis. They converge with AOD9604 in net metabolic outcome but not in receptor or immediate signaling. • Limited or opposite overlap: Ghrelin/GHSR1a agonists generally promote adipogenesis/anti‑lipolysis in adipocytes and increase energy intake; genetic loss of GHSR reduces adiposity. These actions are mechanistically distinct from and largely opposite to AOD9604’s lipolytic, fat‑oxidizing profile.

Key uncertainties and claims Primary literature establishes AOD9604 does not bind/activate GHR and exerts GH‑like lipolytic effects; however, a definitive receptor and intracellular signaling cascade have not been demonstrated. Claims of β3‑adrenergic receptor upregulation and ACC inhibition exist, but direct pathway mapping to cAMP/PKA, JAK2/STAT5, ERK, PI3K, or PDE3B remains to be proven in primary mechanistic studies.

Combination and Synergy#

• Direct combination evidence is limited to a preclinical rabbit osteoarthritis model in which intra-articular AOD9604 combined with high–molecular weight hyaluronic acid (HA) produced superior outcomes versus either monotherapy, consistent with a synergistic or greater-than-additive effect. No retrieved peer-reviewed studies or registered clinical trials evaluated AOD9604 in combination with other “healing peptides” such as BPC‑157, TB‑500 (thymosin β4), GHK‑Cu, IGF‑1/IGF‑1 LR3, CJC‑1295, or ipamorelin.

Combination study details (AOD9604 + HA)

• Model and design: Collagenase-induced knee osteoarthritis in New Zealand white rabbits (n≈32), with four groups receiving weekly intra-articular injections: saline, HA alone, AOD9604 alone, or AOD9604 + HA. Outcomes included blinded histopathological cartilage scoring (modified Mankin), gross morphological scoring, and lameness duration.
• Dosing: AOD9604 0.25 mg per injection; HA 6 mg per injection (Hyruan‑plus®, ~3.0×10^6 Da), administered over 4–7 weeks with assessment at 8 weeks.
• Outcomes: The combination arm demonstrated significantly better gross and histological cartilage scores than either HA or AOD9604 alone, and a shorter lameness period (approximately 11 ± 4 days) compared with saline (≈25 ± 12), HA (≈15 ± 3), and AOD9604 alone (≈16 ± 12). Authors interpret these data as an enhanced effect of the combination, potentially reflecting synergistic chondroprotection and stimulated matrix production.
• Proposed mechanisms: HA may protect chondrocytes from oxidative damage and increase the intra-articular residence time of AOD9604; AOD9604 is reported to promote proteoglycan and collagen production and to support differentiation in musculoskeletal cell types. Together, these complementary actions could underlie the greater-than-additive response observed.

Evidence gaps for other peptide combinations

• BPC‑157, TB‑500 (thymosin β4), GHK‑Cu, IGF‑1/IGF‑1 LR3, CJC‑1295, ipamorelin: No retrieved peer‑reviewed combination studies, preclinical or clinical, evaluating AOD9604 with these agents for musculoskeletal or wound healing outcomes. Patent and clinical‑trial searches did not identify AOD9604 combination data with these peptides. Therefore, no evidence of synergy or complementary benefit can be concluded at this time.

Embedded summary table

• The best available evidence for a combination effect with AOD9604 pertains to HA: in a rabbit osteoarthritis model, AOD9604+HA improved histological and functional outcomes beyond either monotherapy, consistent with synergy or a complementary mechanism. Translational relevance remains uncertain due to preclinical design and small sample size, and there is an absence of combination data with other commonly discussed healing peptides.

Evidence Gaps#

Direct head-to-head comparison studies between HGH Fragment 176-191 and related peptides are limited. Most comparisons are based on separate studies with different methodologies, making direct efficacy comparisons difficult.

Related Reading#

• HGH Fragment 176-191 overview and research guide
• HGH Fragment 176-191 research evidence
• HGH Fragment 176-191 dosing protocols